News

Nonacus Ltd, has launched GALEAS uPCR ESR1, an ultrasensitive qPCR (uPCR) assay developed to detect eleven mutations in the ESR1 gene which are known to be associated with resistance to endocrine therapy October 31, 2024 | COMPANY | NEWS | ONCOLOGY Endocrine therapy is the main therapeutic option for estrogen receptor-positive (ER+), HER2 negative (HER2-) breast cancers, which account…

Nonacus Ltd is proud to announce that it has achieved ISO 27001 certification for its innovative cloud-based GALEAS software and panel design tool. October 22, 2024 | COMPANY | NEWS Nonacus, a provider of innovative genomic products including GALEAS a cloud-based software, is proud to announce that it has achieved ISO 27001 certification, the international standard for…

Written by Saba Shamsuddin SEPT 24, 2024 | COMPANY | NEWS Nonacus Ltd, a leading provider of ultra-sensitive next-generation sequencing (NGS) products, has been awarded the NHS All Wales Medical Genomic Services (AWMGS) tender for familial hypercholesterolemia (FH) testing. The new contract involves the supply of Nonacus’ NGS custom-designed panels for clinical use in FH testing. This…

Written by Saba Shamsuddin JULY 12, 2024 | COMPANY | NEWS Nonacus, a leading provider of innovative genomics solutions worldwide, is proud to announce that Jeff Bousfield has been appointed as the new Chief Executive Officer, effective immediately. This appointment reflects Nonacus’ confidence in the next phase of its expansion and positions the company for even greater…

Written by Victoria Simms May 2023. Reviewed by Celina Whalley April 2024 APRIL 17, 2024 | COMPANY | NEWS May marks Bladder Cancer Awareness Month, four weeks dedicated to raising awareness of this disease, its symptoms, and the current realities for those impacted by bladder cancer both directly and indirectly. As we continue to implement…

April 12, 2024 | COMPANY | NEWS Bladder Cancer Awareness month is quickly approaching and Nonacus is delighted to share that The Daily Telegraph has published an article about recognising the symptoms of bladder cancer, and the importance of early diagnosis of bladder cancer featuring GALEAS Bladder. This piece features insightful interviews from key opinion…

April 2, 2024 | COMPANY | NEWS Genetic testing company, Nonacus, has launched GALEASTM Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumors, allowing clinicians to accurately diagnose cancers and tailor treatments. Comprehensive genomic profiling (CGP) is a well-established technique used to analyse the genomic profile of a tumor, allowing…

January 24, 2024 | COMPANY | NEWS Nonacus has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS HereditaryPlus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations. Eliminating the need for MLPA in hereditary…

October 5, 2023 | COMPANY | NEWS Signal of Strong Commitment to Innovative Medical Services Focused on Early Cancer Detection and Companion Testing Nonacus CEO Chris Sale and Advanced Genomics APAC Co. Ltd. Managing Director Andy Chang Advanced Genomics APAC Co. Ltd. proudly announced today the grand opening of its Taiwan headquarters, marking a significant…

MAY 29, 2023 | COMPANY | NEWS Introducing our new logo and brand identity: reflecting Nonacus’ clinical vision for advanced liquid biopsy testing As we continue to drive innovation in the field, we have honed our focus towards decentralised and cost-effective cancer genomics through our state-of-the-art liquid biopsy testing platform. This rebranding effort signifies our…